TLDR
- Citigroup analyst Geoff Meacham set a Street-high $1,600 price target on LLY, implying 45% upside from current levels.
- Berenberg upgraded LLY to Buy and raised its price target to $1,400, citing ~25% upside potential.
- LLY currently trades at $1,138, up 2% on the day.
- Eli Lilly holds a 60% global market share in weight-loss drugs, with combined quarterly sales of $14.9 billion for its obesity and diabetes treatments.
- LLY carries a consensus Strong Buy rating from 20 Wall Street analysts, with an average price target of $1,375.78.
Eli Lilly stock is getting attention from multiple directions today, with two separate Wall Street upgrades landing within 24 hours.
Citigroup analyst Geoff Meacham set a $1,600 price target on LLY, the highest on Wall Street. That implies about 45% upside from the stock’s current price of $1,138.
Meacham, a five-star rated analyst with a 59% success rate, reiterated a Buy rating alongside the target. He pointed to Eli Lilly’s dominance in the weight-loss drug market as a key reason for his bullish stance.
Eli Lilly holds a 60% global market share in weight-loss drugs. Its obesity and diabetes treatments, Zepbound and Mounjaro, are generating $14.9 billion in combined quarterly sales.
Meacham also noted that LLY stock has dropped 8% over the past month, calling it a buying opportunity for investors.
Berenberg Joins the Bull Camp
Berenberg upgraded LLY to Buy from Hold on Tuesday and raised its price target to $1,400 from $1,220. The firm sees roughly 25% upside from current levels.
Berenberg said its 2026 return on research investment analysis confirms Eli Lilly’s track record of delivering best-in-class returns. It also expects the company to beat its fiscal 2026 guidance.
The firm flagged an upcoming catalyst: an imminent diabetes approval for Foundayo, Eli Lilly’s oral GLP-1 drug. Foundayo posted around $100 million in sales in Q2 2026, with more growth expected after full approval.
Berenberg also highlighted Eli Lilly’s pipeline investments, noting that many new assets carry multibillion-dollar sales potential. The company has committed around $60 billion across more than 25 business development deals year to date.
More Analysts Back the Stock
LLY carries a consensus Strong Buy rating from 20 Wall Street analysts. The breakdown is 18 Buy ratings and two Hold ratings. The average price target across the group sits at $1,375.78, implying about 12% upside from current levels.
BMO Capital and JPMorgan both reiterated positive ratings on LLY recently. Both firms maintain a $1,400 price target, citing growth in the incretin segment.
Eli Lilly’s financial picture backs up the bullish tone. The company posted nearly 50% revenue growth over the last twelve months and carries a perfect Piotroski Score of 9.
The Medicare Bridge program is also driving increased demand for Eli Lilly’s obesity drugs, according to Berenberg.
Rival Novo Nordisk, which holds a 38% global market share in obesity drugs, announced a rebrand, going forward as simply “Novo.” The company is set to outline a detailed business strategy at a Capital Markets Day scheduled for September 21.
Eli Lilly also plans to acquire Merida Biosciences for approximately $2.875 billion in cash to strengthen its autoimmune and allergic disease portfolio.
LLY traded at $1,138.28 on Tuesday, up $22.58, or 2.02%, on the session.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
